LeMaitre Vascular, Inc.

NasdaqGM:LMAT Stock Report

Market Cap: US$1.9b

LeMaitre Vascular Past Earnings Performance

Past criteria checks 5/6

LeMaitre Vascular has been growing earnings at an average annual rate of 17.9%, while the Medical Equipment industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 12.5% per year. LeMaitre Vascular's return on equity is 14.1%, and it has net margins of 22.1%.

Key information

17.92%

Earnings growth rate

15.58%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate12.54%
Return on equity14.08%
Net Margin22.14%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular: Investment Debate Remains In Place

Sep 16

Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors

Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?

Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?

Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?

Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?

Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?

Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?

LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends

Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends

LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year

Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105

Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105

When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease

LeMaitre Vascular: Losing Steam

Jan 15

A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story

Nov 03

LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)

Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
User avatar

Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth

Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings

If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity

LeMaitre Vascular: A Small Cap With Best-In-Industry Growth

Jul 23

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?

Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear

Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?

Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?

Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Oct 27
Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Oct 11
Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

Aug 30
Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?

The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Jul 06
The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence

Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

May 20
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?

Revenue & Expenses Breakdown

How LeMaitre Vascular makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:LMAT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 25241539514
30 Jun 25235479215
31 Mar 25226458716
31 Dec 24220448316
30 Sep 24213418016
30 Jun 24206387717
31 Mar 24200347517
31 Dec 23193307317
30 Sep 23186277016
30 Jun 23177256815
31 Mar 23169216514
31 Dec 22162216213
30 Sep 22160216013
30 Jun 22160225813
31 Mar 22158275512
31 Dec 21154275312
30 Sep 21152285111
30 Jun 21151294910
31 Mar 21135244610
31 Dec 20129214610
30 Sep 20122194710
30 Jun 20115164810
31 Mar 20119185010
31 Dec 1911718499
30 Sep 1911519489
30 Jun 1911118479
31 Mar 1910823469
31 Dec 1810623458
30 Sep 1810321447
30 Jun 1810422447
31 Mar 1810318437
31 Dec 1710117437
30 Sep 179815437
30 Jun 179614436
31 Mar 179312426
31 Dec 168911406
30 Sep 168611396
30 Jun 16829386
31 Mar 16799376
31 Dec 15788375
30 Sep 15767365
30 Jun 15746365
31 Mar 15735364
31 Dec 14704365

Quality Earnings: LMAT has high quality earnings.

Growing Profit Margin: LMAT's current net profit margins (22.1%) are higher than last year (19.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LMAT's earnings have grown by 17.9% per year over the past 5 years.

Accelerating Growth: LMAT's earnings growth over the past year (29.1%) exceeds its 5-year average (17.9% per year).

Earnings vs Industry: LMAT earnings growth over the past year (29.1%) exceeded the Medical Equipment industry 13.6%.


Return on Equity

High ROE: LMAT's Return on Equity (14.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 01:20
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LeMaitre Vascular, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Jan WaldBenchmark Company
Raymond MyersBenchmark Company